Pharnext to Present at 2017 BIO CEO & Investor Conference
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.
The presentation will take place as follows:
- Date : Monday, February 13th , 2017
- Time: 10:00 am ET (4:00 pm CET)
- Venue : The Waldorf Astoria in New York, New York.
If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at email@example.com
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™ . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investors Relations (Europe)
Anne Hennecke, +49 211 529252 22
MC Services AG
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Tony Russo, Ph.D., +1 212-845-4251
Victoria Meissner, M.D., +1 646-942-5627
Financial Communication (France)
Julie Coulot, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
FL-MLB16.10.2017 23:36 | pressemeddelelse
Orlando Melbourne Int’l (MLB) Lands Largest FAA Grant in Its History
IDEMIA16.10.2017 16:36 | pressemeddelelse
Colombia Selects IDEMIA to Upgrade Its Identification and Civil Registry Platform
NY-MUREX16.10.2017 16:02 | pressemeddelelse
ATB Financial Goes-Live on Murex’s SaaS Solution
PRINT24.COM16.10.2017 16:01 | pressemeddelelse
Leave a review on print24.com and win a VW up!
BENTLEY-SYSTEMS16.10.2017 15:54 | pressemeddelelse
Bentley Systems Announces Winners of 2017 Be Inspired Awards
WA-BILL-&-MELINDA-GATES16.10.2017 15:02 | pressemeddelelse
Bill & Melinda Gates Foundation Releases Open-Source Software to Support Efforts that Expand Access to Financial Services in Developing Countries
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum